Masimo (NASDAQ:MASI) Stock Price Expected to Rise, Raymond James Analyst Says

Masimo (NASDAQ:MASI) had its price objective raised by equities research analysts at Raymond James from $170.00 to $194.00 in a research note issued on Friday, Marketbeat reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Raymond James’ price target would indicate a potential upside of 13.47% from the stock’s current price.

Several other research firms have also recently commented on MASI. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler boosted their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. BTIG Research lifted their price target on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company raised their price objective on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $179.67.

Masimo Stock Performance

Shares of Masimo stock opened at $170.97 on Friday. The business’s 50 day moving average price is $162.96 and its 200 day moving average price is $136.30. The company has a market cap of $9.15 billion, a price-to-earnings ratio of 117.91 and a beta of 1.01. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a one year low of $101.61 and a one year high of $180.97.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the prior year, the firm earned $0.63 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. On average, research analysts predict that Masimo will post 4.03 EPS for the current year.

Institutional Investors Weigh In On Masimo

Institutional investors have recently added to or reduced their stakes in the business. NBC Securities Inc. boosted its stake in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares in the last quarter. HHM Wealth Advisors LLC grew its stake in shares of Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares during the period. Headlands Technologies LLC purchased a new position in shares of Masimo in the 2nd quarter valued at about $109,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Masimo in the third quarter valued at about $118,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.